Estimates of costs for modelling return on investment from smoking cessation interventions.
Submitted by admin on Tue, 08/21/2018 - 17:39
Trapero-Bertran, M., et al.
Link to Abstract Summary:
Link to Full Article Free Online:
BACKGROUND AND AIMS: Modelling return on investment (ROI) from smoking cessation interventions requires estimates of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco smoking and costs of implementing cessation interventions for a Europe-wide ROI model [European study on Quantifying Utility of Investment in Protection from Tobacco model (EQUIPTMOD)]. DESIGN: Focused search of administrative and published data. A standardized checklist was developed in order to ensure consistency in methods of data collection. SETTING AND PARTICIPANTS: Adult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For passive smoking-related costs, child population (0-15 years) was also included. MEASUREMENTS: Costs of treating smoking-attributable diseases; productivity losses due to smoking-attributable absenteeism; and costs of implementing smoking cessation interventions. FINDINGS: Annual costs (per case) of treating smoking attributable lung cancer were between euro5074 (Hungary) and euro52 106 (Germany); coronary heart disease between euro1521 (Spain) and euro3955 (Netherlands); chronic obstructive pulmonary disease between euro1280 (England) and euro4199 (Spain); stroke between euro1829 (Hungary) and euro14 880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to be: for standard duration of varenicline between euro225 (England) and euro465 (Hungary); for bupropion between euro25 (Hungary) and euro220 (Germany). Costs (per recipient) of providing behavioural support were also wide-ranging: one-to-one behavioural support between euro34 (Hungary) and euro474 (Netherlands); and group-based behavioural support between euro12 (Hungary) and euro257 (Germany). The costs (per recipient) of delivering brief physician advice were: euro24 (England); euro9 (Germany); euro4 (Hungary); euro33 (Netherlands); and euro27 (Spain). CONCLUSIONS: Costs of treating smoking-attributable diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary, Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to return on investment estimates in support of national or regional policy decisions.